Tredje AP fonden lifted its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,326 shares of the biopharmaceutical company’s stock after acquiring an additional 2,693 shares during the period. Tredje AP fonden’s holdings in Alexion Pharmaceuticals were worth $3,660,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of ALXN. Orion Portfolio Solutions LLC bought a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $29,000. Simon Quick Advisors LLC bought a new stake in Alexion Pharmaceuticals in the 1st quarter worth about $39,000. North Star Investment Management Corp. bought a new stake in Alexion Pharmaceuticals in the 1st quarter worth about $41,000. TCI Wealth Advisors Inc. grew its position in Alexion Pharmaceuticals by 686.0% in the 4th quarter. TCI Wealth Advisors Inc. now owns 393 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 343 shares in the last quarter. Finally, CWM LLC grew its position in Alexion Pharmaceuticals by 172.8% in the 4th quarter. CWM LLC now owns 491 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 311 shares in the last quarter. 89.37% of the stock is owned by institutional investors.
In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker purchased 265,298 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were bought at an average cost of $78.76 per share, for a total transaction of $20,894,870.48. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.03% of the company’s stock.
Shares of ALXN stock traded up $0.36 during trading on Friday, reaching $101.50. 1,052,658 shares of the company’s stock traded hands, compared to its average volume of 2,232,139. The company has a market capitalization of $22.33 billion, a P/E ratio of 9.60, a PEG ratio of 0.79 and a beta of 1.41. The company has a current ratio of 4.35, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. The firm’s 50-day moving average is $100.49 and its 200 day moving average is $102.60. Alexion Pharmaceuticals, Inc. has a 1 year low of $72.67 and a 1 year high of $134.84.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $3.22 EPS for the quarter, beating the Zacks’ consensus estimate of $2.71 by $0.51. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Alexion Pharmaceuticals had a net margin of 44.83% and a return on equity of 21.96%. Alexion Pharmaceuticals’s revenue was up 26.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.39 EPS. As a group, sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 9.94 earnings per share for the current fiscal year.
A number of brokerages have issued reports on ALXN. JPMorgan Chase & Co. reduced their price objective on shares of Alexion Pharmaceuticals from $168.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Royal Bank of Canada began coverage on shares of Alexion Pharmaceuticals in a research report on Friday, January 31st. They issued a “positive” rating and a $135.00 price objective for the company. They noted that the move was a valuation call. Oppenheimer downgraded shares of Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 17th. Nomura Securities reduced their price objective on shares of Alexion Pharmaceuticals from $165.00 to $133.00 and set a “buy” rating for the company in a research report on Monday, February 3rd. Finally, Robert W. Baird dropped their target price on shares of Alexion Pharmaceuticals from $165.00 to $140.00 and set an “outperform” rating on the stock in a research note on Friday, January 31st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $142.09.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: 52 Week Highs
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.